Skip to Content
Merck

F6432

FLT3 (571-993), active, GST tagged human

PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

Synonym(s):

CD135, FLK2, STK1

Slide 1 of 1
Sign In to View Organizational & Contract Pricing

Select a Size

Pricing and availability is not currently available.

About This Item

UNSPSC Code:
51111800
NACRES:
NA.32

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

recombinant

expressed in baculovirus infected Sf9 cells

Quality Level

200

product line

PRECISIO® Kinase

Assay

≥70% (SDS-PAGE)

form

buffered aqueous glycerol solution

specific activity

60-81 nmol/min·mg

mol wt

~73 kDa

UniProt accession no.

P36888

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... FLT3(2322)

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
SRP0349SRP5210F7930
FLT3 (571-993), active, GST tagged human PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

Sigma-Aldrich

F6432

FLT3 (571-993), active, GST tagged human

Flt3 active human recombinant, expressed in baculovirus infected Sf9 cells, ≥80% (SDS-PAGE)

Sigma-Aldrich

SRP0349

Flt3 active human

FLT4 (800-end), active, GST tagged human PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

Sigma-Aldrich

SRP5210

FLT4 (800-end), active, GST tagged human

FGFR3 (397-end), active, GST tagged human PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

Sigma-Aldrich

F7930

FGFR3 (397-end), active, GST tagged human

recombinant

expressed in baculovirus infected Sf9 cells

recombinant

expressed in baculovirus infected Sf9 cells

recombinant

expressed in baculovirus infected Sf9 cells

recombinant

expressed in baculovirus infected Sf9 cells

assay

≥70% (SDS-PAGE)

assay

≥80% (SDS-PAGE)

assay

≥70% (SDS-PAGE)

assay

≥70% (SDS-PAGE)

mol wt

~73 kDa

mol wt

54.2 kDa

mol wt

~85 kDa

mol wt

~73 kDa

form

buffered aqueous glycerol solution

form

aqueous solution

form

buffered aqueous glycerol solution

form

buffered aqueous glycerol solution

UniProt accession no.

P36888

UniProt accession no.

P36888

UniProt accession no.

-

UniProt accession no.

P22607

Gene Information

human ... FLT3(2322)

Gene Information

human ... FLT3(2322)

Gene Information

human ... FLT4(2324)

Gene Information

human ... FGFR3(2261)

General description

FLT3 (fms-related tyrosine kinase 3) is a tyrosine kinase receptor and the gene is localized to human chromosome 13q12. The encoded protein is composed of 993 amino acids, and consists of five immunoglobulin (Ig)-like domains in its exoplasmic region. It is also composed of a transmembrane region, a juxtamembrane domain, and two tyrosine kinase domains in its intracellular domain. The tyrosine kinase domains are linked via a kinase-insert domain.[1]

Biochem/physiol Actions

FLT3 (fms-related tyrosine kinase 3), upon interaction with its ligand, undergoes conformational changes to form homodimers. This results in phosphorylation and activation of downstream signaling pathways including phosphatidylinositol 3-kinase (PI3K/AKT), mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and signal transducer and activator of transcription 5 (STAT5) pathways.[2] Internal tandem duplication (ITD) mutation or a point mutation in juxtamembrane domain-coding region or within the activation loop domain, respectively, of this gene lead to its constitutive action. FLT3/ITD mutation is associated with later stages of acute myeloid leukemia (AML) pathogenesis. These patients have poor prognosis.[1]

Physical form

Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.

Legal Information

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H317,H319,H412

Hazard Classifications

Aquatic Chronic 3 - Eye Irrit. 2 - Skin Sens. 1

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SLBL9785V
SLBJ4126V
SLBG9995V
SLBF6761V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J L Christensen et al.
Proceedings of the National Academy of Sciences of the United States of America, 98(25), 14541-14546 (2001-11-29)
Clonogenic multipotent mouse hematopoietic stem cells (HSCs) and progenitor cells are contained within the c-kit(+) (K) lineage(-/lo) (L) Sca-1(+) (S) population of hematopoietic cells; long-term (LT) and short-term (ST) HSCs are Thy-1.1(lo). c-kit is a member of the receptor tyrosine
D Gary Gilliland et al.
Current opinion in hematology, 9(4), 274-281 (2002-06-04)
FLT3 is the most frequently mutated gene in cases of acute myelogenous leukemia (AML). About 30 to 35% of patients have either internal tandem duplications (ITDs) in the juxtamembrane domain or mutations in the activating loop of FLT3. FLT3 mutations
Alexa S Green et al.
Science advances, 1(8), e1500221-e1500221 (2015-11-26)
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide short-term disease control, but relapse invariably occurs within months. Pim
D L Stirewalt et al.
Blood cancer journal, 4, e208-e208 (2014-05-03)
Patients with high FLT3 internal tandem duplication allelic ratios (FLT3/ITD-ARs) have a poor prognosis. Single-nucleotide polymorphism/comparative genomic hybridization, single-cell PCR and colony-forming assays were used to evaluate genotypic evolution of high FLT3/ITD-ARs in 85 acute myeloid leukemia (AML) patients. Microarrays
Yesid Alvarado et al.
Cancer, 120(14), 2142-2149 (2014-04-17)
FLT3-internal tandem duplication (ITD) mutations are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 inhibitors have shown clinical activity in AML with FLT3-ITD, but responses are usually short-lived. This study examined 69 FLT3-mutated patients with AML

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service